Mark Ereth

Dr. Mark Ereth is the Chief Medical Officer at InSitu Biologics and a leading expert in the field of precision medicine. Mark has over 20 years of experience in the healthcare industry, with a focus on improving clinical outcomes and reducing costs.

Dr. Ereth began their career as a hospital administrator, where they quickly realized the potential for data analytics to improve patient care. Mark founded ApriHealth, Inc. in 2016, with the goal of using data to help hospitals deliver value-based care. Under their leadership, ApriHealth became a leading provider of data analytics and clinical decision support tools, helping hospitals across the country reduce over-utilization and improve clinical outcomes.

In 2020, Dr. Ereth sold ApriHealth to InSitu Biologics and joined their team as Chief Medical Officer. In their current role, they are responsible for leading InSitu's efforts to develop and commercialize new precision medicine therapies.

Dr. Ereth is a passionate advocate for the use of data and analytics in healthcare. Mark is a frequent speaker at national conferences, and their work has been featured in numerous publications, including The Wall Street Journal and Forbes.

Mark Ereth began their educational career by obtaining their MD from the University of North Dakota School of Medicine and Health Sciences. Mark then pursued a career in anesthesiology and obtained their certification from the American Board of Anesthesiology.

Mark Ereth works with Kevin Barrett - Chief Operating Officer, Bill Taylor - Chief Science Officer. Mark Ereth reports to Kevin Bassett, President & CEO. A direct report to Mark Ereth is and Kay Warnott - VP, Clinical Operations.